NCT00453674Recruiting
German Adrenocortical Carcinoma Registry
Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
Basic objective of the German Adrenocortical Carcinoma Registry is to improve the care of patients with adrenocortical cancer. The registration of as many patients as possible helps to collect data for the prognosis and prospects of success regarding different treatment plans. This data will be taken into consideration for planning prospective studies. With this registry, the recruitment of patients for prospective studies will be significantly facilitated. In this way - and in cooperation with networks in other countries (e.g. in Italy and France) - a structure allowing systematic improvement of therapy will be developed.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 28 Mar 2007
- Start date
- 1 Jan 2003
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- University of Wuerzburg
- Diseases
- Childhood cancers
- NCT number
- NCT00453674
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Jan 2003 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Histologically confirmed diagnosis of adrenocortical carcinoma
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Wuerzburg Coordinator of this site? Confirm its status | Würzburg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.